G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
Fadi Braiteh,Andres O. Soriano,Guillermo Garcia-Manero,David S. Hong,Marcella M. Johnson,Leandro de Padua Silva,H. Yang,Stefanie Alexander,Johannes E. A. Wolff,Razelle Kurzrock +9 more
TL;DR: The combination of 5- AZA and valproic acid is safe at doses up to 75 mg/m2 for 5-AZA in patients with advanced malignancies, and a significant decrease in global DNA methylation and induction of histone acetylation were observed.
Journal ArticleDOI
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
Hagop M. Kantarjian,Susan O'Brien,Jorge E. Cortes,Sergio Giralt,Mary Beth Rios,Jianqin Shan,Francis J. Giles,Deborah A. Thomas,Stefan Faderl,Marcos de Lima,Guillermo Garcia-Manero,Richard E. Champlin,Ralph B. Arlinghaus,Moshe Talpaz +13 more
TL;DR: It is concluded that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD.
Journal ArticleDOI
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Detlef Haase,Kristen E. Stevenson,Donna Neuberg,Jaroslaw P. Maciejewski,Aziz Nazha,Mikkael A. Sekeres,Benjamin L. Ebert,Guillermo Garcia-Manero,Claudia Haferlach,Torsten Haferlach,Wolfgang Kern,Seishi Ogawa,Yasunobu Nagata,Kenichi Yoshida,Timothy A. Graubert,Matthew J. Walter,Alan F. List,Rami S. Komrokji,Eric Padron,David A. Sallman,Elli Papaemmanuil,Peter J. Campbell,Michael R. Savona,Adam C. Seegmiller,Lionel Adès,Pierre Fenaux,Lee-Yung Shih,David T. Bowen,Michael J. Groves,Sudhir Tauro,Michaela Fontenay,Olivier Kosmider,Michal Bar-Natan,David P. Steensma,Richard Stone,Michael Heuser,Felicitas Thol,Mario Cazzola,Luca Malcovati,Aly Karsan,Christina Ganster,Eva Hellström-Lindberg,Jacqueline Boultwood,Andrea Pellagatti,Valeria Santini,Lynn Quek,Paresh Vyas,Heinz Tüchler,Peter L. Greenberg,Rafael Bejar +49 more
TL;DR: The poor risk associated with CK-MDS is driven by its association with prognostically adverse TP53 mutations and can be refined by considering clinical and karyotype features.
Journal ArticleDOI
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A. Sallman,Adam S. Asch,Monzr M. Al Malki,Daniel J. Lee,William B. Donnellan,Guido Marcucci,Suman Kambhampati,Naval Daver,Guillermo Garcia-Manero,Rami S. Komrokji,Joanna Van Elk,Ming Lin,Jens-Peter Volkmer,Chris H. Takimoto,Mark P. Chao,Paresh Vyas +15 more
TL;DR: Magrolimab+AZA was well-tolerated with a safety profile similar to AZA monotherapy, and time to response was more rapid (median 1.9 mos) than expected for AZA alone.
Journal ArticleDOI
Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Guillermo Garcia-Manero,Francesco Paolo Tambaro,Nebiyou B. Bekele,Hui Yang,Farhad Ravandi,Elias Jabbour,Gautam Borthakur,Tapan M. Kadia,Marina Konopleva,Stefan Faderl,Jorge E. Cortes,Mark Brandt,Yumin Hu,Deborah McCue,Willie Newsome,Sherry Pierce,Marcos de Lima,Hagop M. Kantarjian +17 more
TL;DR: The combination of vorinostat with idarubicin and cytarabine is safe and active in AML and levels of NRF2 and CYBB were associated with longer survival.